Cannabinoids in ADHD: randomized controlled trial

Introduction and clinical context

The study Cannabinoids in ADHD: randomized controlled trial (Eur Neuropsychopharmacol · 2017) is part of the scientific research on the use of cannabinoids in adhd.

Attention-deficit/hyperactivity disorder (ADHD) is a still-nascent area of medical-cannabis research. A randomized trial with nabiximols evaluated cognition and symptoms in adults, and studies explore the therapeutic reasons reported by people with ADHD who use cannabis. The evidence is preliminary and does not support cannabis as a first-line treatment; ADHD management should follow specialized guidance.

Understanding what science shows about the use of cannabinoids in adhd helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This clinical trial was conducted in a controlled manner, comparing the treatment with a reference group. 6-week RCT (Sativex) evaluating cognition and symptoms in adults with ADHD. The blinded, controlled design reduces bias and increases the reliability of the finding. Results from controlled trials like this are especially valuable for guiding therapeutic decisions.

Mechanism of action and safety

The research hypothesis links the endocannabinoid system to the modulation of dopaminergic signaling involved in attention and impulse control. The evidence, however, is preliminary, and there is a specific concern: in adolescents and young adults, THC-rich cannabis use can impair cognition and brain development. Safety, therefore, advises against self-medication. ADHD has treatments of established efficacy, and cannabinoids are not first-line; any studies occur in a controlled context, with specialized assessment.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (Eur Neuropsychopharmacol · 2017). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis treat ADHD?

The evidence is preliminary and does not support cannabis as first-line; management should be specialized.

What has already been studied?

A trial with nabiximols in adults and studies on the reported reasons for use.